FulvestrantA Review of its Use in the Management of Hormone Receptor-Positive Metastatic Breast Cancer in Postmenopausal Women

被引：0
|
作者：
Jamie D. Croxtall
Kate McKeage
机构：
[1] Adis,
[2] a Wolters Kluwer Business,undefined
来源：
Drugs | 2011年 / 71卷
关键词：
Tamoxifen; Postmenopausal Woman; Anastrozole; Exemestane; Fulvestrant;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Fulvestrant (Faslodex®) is an intramuscularly administered steroidal estrogen receptor antagonist that is devoid of any known estrogen agonist effects. It is indicated as second-line therapy for the treatment of postmenopausal women with hormone receptor-positive advanced breast cancer who have progressed following prior endocrine therapy.
引用
收藏
页码：363 / 380
页数：17
相关论文
共 50 条
  • [41] Statin use in patients with hormone receptor-positive metastatic breast cancer treated with everolimus and exemestane
    Lee, Kyoungmin
    Noh, Eunjin
    Moon, Seok Joo
    Joo, Yoonjung Yoonie
    Kang, Eun Joo
    Seo, Jae Hong
    Park, In Hae
    CANCER MEDICINE, 2023, 12 (05): : 5461 - 5470
  • [42] Adjuvant Systemic Therapy for Postmenopausal, Hormone Receptor-Positive Early Breast Cancer
    Johnston, Stephen R. D.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (01) : 89 - 102
  • [43] Correction to: Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer
    Ahrong Ham
    Min Hwan Kim
    Gun Min Kim
    Jee Hung Kim
    Jee Ye Kim
    Hyung Seok Park
    Seho Park
    Young Up Cho
    Byeong Woo Park
    Seung Il Kim
    Joohyuk Sohn
    Breast Cancer Research and Treatment, 2020, 183 : 493 - 493
  • [44] Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: a systematic review
    S. J. Ioannides
    P. L. Barlow
    J. M. Elwood
    D. Porter
    Breast Cancer Research and Treatment, 2014, 147 : 237 - 248
  • [45] Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: a systematic review
    Ioannides, S. J.
    Barlow, P. L.
    Elwood, J. M.
    Porter, D.
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 147 (02) : 237 - 248
  • [46] Efficacy of chemotherapy after hormone therapy for hormone receptor-positive metastatic breast cancer
    Mori, Ryutaro
    Nagao, Yasuko
    SAGE OPEN MEDICINE, 2014, 2
  • [47] Optimal Timing of Delivery for Women with Hormone Receptor-Positive Breast Cancer
    Kuo, Kelly
    Senz, Kayli
    Caughey, Aaron B.
    OBSTETRICS AND GYNECOLOGY, 2018, 131 : 60S - 60S
  • [48] Everolimus in Combination with Exemestane: A Review of its Use in the Treatment of Patients with Postmenopausal Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
    Sohita Dhillon
    Drugs, 2013, 73 : 475 - 485
  • [49] Everolimus in Combination with Exemestane: A Review of its Use in the Treatment of Patients with Postmenopausal Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
    Dhillon, Sohita
    DRUGS, 2013, 73 (05) : 475 - 485
  • [50] The budget impact of the DiviTum®TKa assay in postmenopausal women with hormone receptor positive metastatic breast cancer
    Guzauskas, Gregory F.
    Carlson, Josh J.
    Dann, Robert A.
    Ramsey, Scott D.
    CANCER RESEARCH, 2022, 82 (04)
12345